Clinicians Trial brief

REDEFINE 4: a head-to-head readout

Originally posted Feb 2026 · By Joe Zucchi, PA-C, MPAS

Download JPG ↓Original LinkedIn post ↗

1280 × 1280 px · PDF includes the original image and a link to this page.

Joe’s commentary

About this visual

Joe’s summary of CagriSema and tirzepatide results, with both estimands shown.

The results are in for the REDEFINE 4 clinical trial, which was a major head-to-head study comparing Novo Nordisk's CagriSema against Eli Lilly's Zepbound (tirzepatide).

This was one of the most anticipated matchups in obesity medicine because it tested two powerful weight loss therapies currently in development or on the market. In this 84-week study of over 800 adults, Zepbound (tirzepatide) came out on top.

While CagriSema showed impressive results, it did not meet the criteria for non-inferiority. Here is the breakdown of the weight loss results:
Full adherence (efficacy estimand):
• Tirzepatide: 25.5 percent
• CagriSema: 23.0 percent
Treatment-regimen estimand (regardless of adherence):
• Tirzepatide: 23.6 percent
• CagriSema: 20.2 percent

Both medications showed a similar safety profile, with the usual gastrointestinal side effects that we typically see with this class of drugs.

The main takeaway here is that while CagriSema is clearly an effective tool, this specific dose was not able to outpace tirzepatide. Novo Nordisk has already announced they will be starting a new trial with 7.2mg semaglutide to see if they can close that gap.

I put together an infographic that summarizes the data.

In other news today, Eli Lilly has officially launched the Zepbound KwikPen, allowing for multiple doses in a single pen as an alternative option to the vials through LillyDirect. Link in comments for more info.

Sources & further reading

Original LinkedIn post and discussion ↗

Additional references appear in the infographic and the original LinkedIn discussion.

Related visuals

REDEFINE 4: a head-to-head readout

Pinch to zoom on touch devices. Open full image ↗